Back to Search Start Over

Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome: a comprehensive update

Authors :
Michael B. Petersen
Mats Brännström
Morten Herlin
Source :
Herlin, M K, Petersen, M B & Brännström, M 2020, ' Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome: a comprehensive update ', Orphanet Journal of Rare Diseases, vol. 15, 214 . https://doi.org/10.1186/s13023-020-01491-9, Herlin, M K, Petersen, M B & Brännström, M 2020, ' Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome : a comprehensive update ', Orphanet Journal of Rare Diseases, vol. 15, no. 1, 214 . https://doi.org/10.1186/s13023-020-01491-9, Orphanet Journal of Rare Diseases, Vol 15, Iss 1, Pp 1-16 (2020), Orphanet Journal of Rare Diseases
Publication Year :
2021
Publisher :
Bioscientifica, 2021.

Abstract

Background Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome, also referred to as Müllerian aplasia, is a congenital disorder characterized by aplasia of the uterus and upper part of the vagina in females with normal secondary sex characteristics and a normal female karyotype (46,XX). Main body The diagnosis is often made during adolescence following investigations for primary amenorrhea and has an estimated prevalence of 1 in 5000 live female births. MRKH syndrome is classified as type I (isolated uterovaginal aplasia) or type II (associated with extragenital manifestations). Extragenital anomalies typically include renal, skeletal, ear, or cardiac malformations. The etiology of MRKH syndrome still remains elusive, however increasing reports of familial clustering point towards genetic causes and the use of various genomic techniques has allowed the identification of promising recurrent genetic abnormalities in some patients. The psychosexual impact of having MRKH syndrome should not be underestimated and the clinical care foremost involves thorough counselling and support in careful dialogue with the patient. Vaginal agenesis therapy is available for mature patients following therapeutical counselling and education with non-invasive vaginal dilations recommended as first-line therapy or by surgery. MRKH syndrome involves absolute uterine factor infertility and until recently, the only option for the patients to achieve biological motherhood was through gestational surrogacy, which is prohibited in most countries. However, the successful clinical trial of uterus transplantation (UTx) by a Swedish team followed by the first live-birth in September, 2014 in Gothenburg, proofed the first available fertility treatment in MRKH syndrome and UTx is now being performed in other countries around the world allowing women with MRKH syndrome to carry their own child and achieve biological motherhood. Conclusion Several advances in research across multiple disciplines have been made in the recent years and this kaleidoscopic review provides a current status of various key aspects in MRKH syndrome and provides perspectives for future research and improved clinical care.

Details

ISSN :
16624009
Database :
OpenAIRE
Journal :
Yearbook of Paediatric Endocrinology
Accession number :
edsair.doi.dedup.....a4320cfc1073f853aae1cca741e33317